{"name":"Crestone, Inc","slug":"crestone-inc","ticker":"","exchange":"","domain":"","description":"Crestone, Inc is a biotechnology company focused on the development of novel therapeutics. The company has two drugs in its pipeline, both targeting specific medical conditions with potential for significant patient impact.","hq":"","founded":0,"employees":"N/A","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMi-AFBVV95cUxNUWxocS1uZjlveVdGRU85S0lMMDZ1cXZqNHVnNzRUdFZUVGFVWGVmNWtZTElMRTEwb1dlZ2FIT0tvRjlZMUJoTjgwSEtWX0l2aFdGRTgzUFROT3ZsajZEQ0RxSkQ3eDFtZWs3N3JoLWJpTURadkhLSkVYY09Kai02VXBvTUdJS2cyRkRmMlp4S0NVMXA5LVVLcm9Nc1I2R1RBTE5zUTBvckd0QWFYQWxjNFRVVlVIX0ZvSWRrWlhPTmtWT3NZR3hwejRIRDJZUlZxZ05pd0hFbEZndjBuYXllNE5yQThyckQ0dW91aEMyeEhpOWlBTEhKSQ?oc=5","date":"2026-04-07","type":"pipeline","source":"Barchart.com","summary":"Clostridium Difficile Infections Treatment Pipeline Shows Strong Momentum as 20+ Pharma Companies in the Race | DelveInsight - Barchart.com","headline":"Clostridium Difficile Infections Treatment Pipeline Shows Strong Momentum as 20+ Pharma Companies in the Race | DelveIns","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipwJBVV95cUxPQkc2bnQySi1zVl9pRmhYOVkwUXhEdlJua3UtYWd6eTY1TS1Iazhsa1BMN3BuaWhNdjdNTkZzX0xsX01hMkZqakRSMTFONEZ3bHpSdVVXLTdtcm1nZTQxY1NnUFdzejhJYmx6VjFVbndZdnFVVlVZX3VOMWhWdmMtblU1TmVFSkliMjFkVXctd09CU0xvbUdkUElNRHpsQU50eWhUcW9qd0w3ZkZWUWZuU1dtUVYwMG9YNkxTcFUyQjhUbHo2X1FnUkpSWUJaQmhPcmFpdmtfMjJJc0t0bXM5czdkWTc2S1otTHRhd2tISklSZkdobGRXYUJ2V19heWVZYzJ6NXdmNUdRZjF0TTltSmRpc3Nld0NhU2EwRTMzQjVESk16UXVB?oc=5","date":"2026-03-09","type":"trial","source":"Business Wire","summary":"Crestone Announces Positive Data from Phase 2 Clinical Trial of CRS3123 for C. difficile Infections Published in The Lancet Infectious Diseases - Business Wire","headline":"Crestone Announces Positive Data from Phase 2 Clinical Trial of CRS3123 for C. difficile Infections Published in The Lan","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMiekFVX3lxTFBpU0J5YmVFaFFOTmMzbmxTaG1na0ZxVXZlVERYXy1zbERHbk9sX1d0Rnpuc2dBUGRPYjVwLUczTGxFRG9Vb1B2SWt6bVZ1QndwTjgtWDBabVJndWM3TU9KazFYTVh2YUFBWVVxSVZUTUk0ZVRWbFVGNDBn?oc=5","date":"2025-06-28","type":"pipeline","source":"Kroll","summary":"The Opinions Practice of Kroll Rendered a Fairness Opinion to capiton in Connection with the €248 million GP-led Secondary Transaction of Raith and AEMtec - Kroll","headline":"The Opinions Practice of Kroll Rendered a Fairness Opinion to capiton in Connection with the €248 million GP-led Seconda","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi8gFBVV95cUxOOHpfd2MzVkN4OVlnNUJzRWNUY1JFQ1lscW5EM0k2Vi13Tkwta3VGY2o0NFNDenBNT1JsLURqRlEzWnlYbUZ4dTk3RlBuU3VvaHVjcDlvbDFaUGpadGR4d3l5dUczZWduQTkzMi1qZnJTa1NpSEloY3JwVkxNcXRqZ1dJYVBwTGZYa0IzanRjelEyVVRDYWJCZzRILWVjck94WmJwSFZKMDFBV1EtUUxnUEg4eE1FR0FZX2VfbWJhRGw5VWdfUFRVMndPNEdWTmJEQ2xtbjJQaXdzUXQzUC1jWjBqWHhVUTh4TXFUOWptTk55QQ?oc=5","date":"2024-09-05","type":"trial","source":"Business Wire","summary":"Crestone Announces Positive Data From Phase 2 Clinical Trial of CRS3123 for C. Difficile Infections (CDI) - Business Wire","headline":"Crestone Announces Positive Data From Phase 2 Clinical Trial of CRS3123 for C. Difficile Infections (CDI)","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMisgFBVV95cUxQd3BmMk1wSmgxVmR3OHRpOWZ4ckJhSFZ1T1F6WlhmdHFldkVtU2RyVHBSQWI4aDROTTByY1dRd2VyQmw2bXFZdlVreTk0TTZSM25yWDd1bnRvMjM3Vm9aUE9LUkFtY2tEUTRhUUtNcUxPbVUwYkdLT0lvTkJjNW1PenJORWRYeXpmVmNYUi1NOWJ5eDNJSXAyX1lfT1lkVl9kMGpOX2NBOGlrSXV0aUF2RzVR?oc=5","date":"2021-10-11","type":"deal","source":"PR Newswire","summary":"Crestone Services Group Acquires Americom Technology, Inc. - PR Newswire","headline":"Crestone Services Group Acquires Americom Technology, Inc.","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitwFBVV95cUxQbmJzZjFmTE1QTmNGRWRYZkZtajJoZDRSeGNYZWlodW1vOWFjTFBLSkZuaGZXcEZjaHRxUUpKa0FJbFotM05EaUZrTjM3ZDVJb3FJQTJDZUktZDBqdzZCLS1rWHNHRXVveGlwY0FSTDY4UHhZdk5nTmE4S2lMYWhsNmpaWVRnLWpXSDNGU2V5OFJvRHN3ZGY5OGZDWGhJd1ZfMWlWdEdyV1RLMGFmYVRTVG9xcFlLZG8?oc=5","date":"2021-08-05","type":"pipeline","source":"PR Newswire","summary":"Acurx Pharmaceuticals Joins the Antimicrobials Working Group - PR Newswire","headline":"Acurx Pharmaceuticals Joins the Antimicrobials Working Group","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi1wFBVV95cUxNTnlieFN1S1M0THg1ajJyMmRHYW5SY0tCMmVaZ2ZvaTFrRWVkQUlfbndVUEtTMGxfQ1c4aHhtSmN3b200OHpOVHk5bnBOeV92cEJIU0s2MjlXVUZfcV9WejNBR0ptTGY3RmcxVHROa2w0ZEFRMERYNjhsRW9heUVSVWFGRnVlWHVIQm1DRjYwZnFRa3h0Z09QM0NROEl0blFHaW9uWUp2akJ1ZU56U08zd0dRc1VKSHpRWS1LNW1ZZUFWekVPLTQzRXZ0Q3hDTGlpd1kya0l4aw?oc=5","date":"2020-01-22","type":"deal","source":"PR Newswire","summary":"Crestone Services Group Acquires HDD Specialists, LLC And Underground Specialties, Inc. - PR Newswire","headline":"Crestone Services Group Acquires HDD Specialists, LLC And Underground Specialties, Inc.","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMib0FVX3lxTFAzWlYzWEtwMmFOVk5ZTXRFdEh6aGdTMVpneXpSdlJDZjRMRVNxT2hpMEU4RFgtREswcjViYWhLVmx0VXE5MWJXY3d5dGhWbUlZVmUwX2JreGR5MmotQVpWZXM4U25fUVRZZHJqYXdBZw?oc=5","date":"2020-01-06","type":"pipeline","source":"Kroll","summary":"Duff & Phelps Provided a Fairness Opinion to capiton in Connection with the Single-Asset Secondary Transaction of KD Pharma Group - Kroll","headline":"Duff & Phelps Provided a Fairness Opinion to capiton in Connection with the Single-Asset Secondary Transaction of KD Pha","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMid0FVX3lxTE9uYXlSa0RlMmV1U0dDOTJWSGVOTTBJdFBMYUFMV01kVUZWN1Fwa09iV1JkTlI2ZzY3YnFCb2ZZV2MtLTBGNXVrcFNYdy1CRDdlZjJMb3JNS0hBYm13dkdJMnRmWk5mcDJ4ek1wZlA3N1c1WHdRei1v?oc=5","date":"2019-05-13","type":"pipeline","source":"Kroll","summary":"Duff & Phelps Advised mscripts, LLC on Its Sale to Cardinal Health, Inc. - Kroll","headline":"Duff & Phelps Advised mscripts, LLC on Its Sale to Cardinal Health, Inc.","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilwFBVV95cUxPQjRveW9yZWpLMmdpWUpVSGhfd3FCTUdlal9DbGZwTE5tSHdndEljajBnUTNzemIyaUtjNmRqRm9KYVJBVVRVS3JuYTV2bmFid3JsSGllWGJnM1RWVjR2ZFdIeDFTLWYxdkNIR2ZrVzl0akJnRVVuMU9HVmdJZTgwLXFOWGhURXNfc1JqWVdiMllKdFhIQ3U0?oc=5","date":"2014-07-11","type":"trial","source":"Global Biodefense","summary":"NIH Launches Phase I Study for Clostridium Difficile Drug - Global Biodefense","headline":"NIH Launches Phase I Study for Clostridium Difficile Drug","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiiAFBVV95cUxOYmtyRHV3TnY5eW5IMmhUSGdRUU5nSWN0WFBmYWwzNkRJN3dGNVBPUnlTTjdVXzVIOFhNNnR3cXVuSXZpQ3QxeXRlUkRmazJkVF9FdnRCckh5NUJvdHRxU2JtOHppOEJyV19ZQlZlejRsQzU3U2pHMzg1RHEtNnVmbGVYRDhIM2F5?oc=5","date":"2014-07-01","type":"pipeline","source":"Kroll","summary":"Sell Side Advisor Kirby Lester Holdings LLC - Kroll","headline":"Sell Side Advisor Kirby Lester Holdings LLC","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilAFBVV95cUxQTENYMWZkT2p2N0E0MWU5dnBwZWQtNVBIcTFrOExyWmUyVWZrRXVEYURxTUhuMU1lS1VBX3lrcHA5M0ZtSjVHRmppeW1oV2tYOGNoWnAwN0cteU4yN0hXSElGRXJPcHpsVzYyT3MwY1dUd3otTWZpTmJtN3JpVFpyQlh5dC1BMjBDQTBnSGM5ZVJ5ZGt4?oc=5","date":"2013-07-16","type":"pipeline","source":"Kroll","summary":"Sell Side Advisor - Comprehensive Clinical Development - Kroll","headline":"Sell Side Advisor - Comprehensive Clinical Development","sentiment":"neutral"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":2,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}